Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2008 4
2009 1
2010 4
2011 6
2012 5
2013 7
2014 6
2015 6
2016 4
2018 1
2019 8
2020 8
2021 5
2022 5
2023 1
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma.
Conteduca V, Scarpi E, Farolfi A, Brighi N, Rossi L, Gurioli G, Lolli C, Schepisi G, Bleve S, Gianni C, Virga A, Altavilla A, Burgio SL, Menna C, De Giorgi U. Conteduca V, et al. Among authors: altavilla a. Front Oncol. 2021 Jul 21;11:716467. doi: 10.3389/fonc.2021.716467. eCollection 2021. Front Oncol. 2021. PMID: 34367999 Free PMC article.
CAR-T cell therapy: a potential new strategy against prostate cancer.
Schepisi G, Cursano MC, Casadei C, Menna C, Altavilla A, Lolli C, Cerchione C, Paganelli G, Santini D, Tonini G, Martinelli G, De Giorgi U. Schepisi G, et al. Among authors: altavilla a. J Immunother Cancer. 2019 Oct 16;7(1):258. doi: 10.1186/s40425-019-0741-7. J Immunother Cancer. 2019. PMID: 31619289 Free PMC article. Review.
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.
Bracarda S, Sisani M, Marrocolo F, Hamzaj A, Del Buono S, Altavilla A. Bracarda S, et al. Among authors: altavilla a. Expert Rev Anticancer Ther. 2014 Nov;14(11):1283-94. doi: 10.1586/14737140.2014.965686. Epub 2014 Oct 29. Expert Rev Anticancer Ther. 2014. PMID: 25353258 Review.
Plasma Androgen Receptor in Prostate Cancer.
Conteduca V, Gurioli G, Brighi N, Lolli C, Schepisi G, Casadei C, Burgio SL, Gargiulo S, Ravaglia G, Rossi L, Altavilla A, Farolfi A, Menna C, Colangione SP, Pulvirenti M, Romeo A, De Giorgi U. Conteduca V, et al. Among authors: altavilla a. Cancers (Basel). 2019 Nov 4;11(11):1719. doi: 10.3390/cancers11111719. Cancers (Basel). 2019. PMID: 31689899 Free PMC article. Review.
Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
Maiorano BA, De Giorgi U, Roviello G, Messina C, Altavilla A, Cattrini C, Mennitto A, Maiello E, Di Maio M. Maiorano BA, et al. Among authors: altavilla a. ESMO Open. 2022 Oct;7(5):100575. doi: 10.1016/j.esmoop.2022.100575. Epub 2022 Sep 22. ESMO Open. 2022. PMID: 36152486 Free PMC article. Review.
Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study.
Farolfi A, Gentili N, Testoni S, Rusconi F, Massa I, Danesi V, Altavilla A, Cursano MC, Gurioli G, Burgio SL, Ibarburu GH, De Giorgi U. Farolfi A, et al. Among authors: altavilla a. iScience. 2024 Apr 6;27(5):109680. doi: 10.1016/j.isci.2024.109680. eCollection 2024 May 17. iScience. 2024. PMID: 38646168 Free PMC article.
66 results